Stock Ratings / Health Care / GANX / options

IBIO (23) CNTB (35) XLO (27) PLRX (44) ⌘ Pro Terminal →

Gain Therapeutics Inc. (GANX) Options Positioning, Max Pain & Unusual Sweeps

$1.13 -5.04% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.12

Gain Therapeutics Inc. (GANX) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $51.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on GANX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is GANX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Gain Therapeutics Inc. (NASDAQ: GANX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $1.13 (-5.04% 1D, market cap $51.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, GANX ranks #511 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does GANX compare to IBIO and CNTB in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GANX carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IBIO (iBio Inc.) holds a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $52.3M) and CNTB (Connect Biopharma Holdings Limited) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $52.6M). Among the 5-stock peer group, GANX leads on earnings multiple (N/A) while GANX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for GANX?

▼

Per GANX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001819411), Gain Therapeutics Inc. generated $0 in revenue, -$20.2M in net income, and -$18.5M in free cash flow against $22.8M in total assets and $300.1K in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.12 (-1.10%)🧬 Disciplined Float (+0.16% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE-8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GANX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (41/100 Composite)

🔍 WHY GANX SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (32% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Macro Regime Fit+11/20 pts (27% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 34 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$1.57-20.4% Next Q

Q2 (-2Q)

Grade D$1.25-8% Next Q

Q3 (-1Q)

Grade D$1.15-1.7% Next Q

Current

Grade D-$1.13-7.2% Hist 90D α

Trajectory: D (49) → D- (41)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a GANX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While GANX currently carries a cautious 41/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.61) and Max Pain ($1.19) forces dealer call-delta covering toward $4.56.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $GANX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “GANX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 41%NO 59%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (GANX)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for GANX.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GANX)

✓Walkthrough of GANX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

GANX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -40.53%▼ SUPPORT BREAKDOWN

2026-11-02O $1.19H $1.19L $1.13C $1.13VOL 177.2K

RES: $2.60SUP: $1.56SMA50: $1.61SMA200: $1.86

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GANX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GANX Butterfly Map → + Track GANX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on GANX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GANX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for GANX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GANX)

Health Care Rank #511 of 1016 ⚔️ IBIO vs GANX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GANX vs. IBIO, CNTB, XLO, PLRX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Gain Therapeutics Inc. (GANX) ranks #511 by composite RQD confidence (41/100, grade D-) and #746 by equity capitalization ($51.9M). Within this direct 5-issuer industry benchmark cohort, GANX leads on earnings valuation at N/A trailing P/E, while GANX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PLRX currently holds the highest overall quantitative score in the immediate peer group at 44/100 (D) compared with GANX at 41/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
GANX ACTIVE Gain Therapeutics Inc.	D-	41/100	—	—	-35.0%	-5.04%	$51.9M	Benchmark Subject
IBIO iBio Inc.	E	23/100	—	—	-35.0%	-5.52%	$52.3M	/ibio-vs-ganx →
CNTB Connect Biopharma Holdings Limited	D-	35/100	—	—	-35.0%	-3.97%	$52.6M	/cntb-vs-ganx →
XLO Xilio Therapeutics Inc.	E	27/100	—	—	-35.0%	+3.35%	$51.1M	/xlo-vs-ganx →
PLRX Pliant Therapeutics Inc.	D	44/100	—	—	-35.0%	-0.13%	$53.3M	/plrx-vs-ganx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001819411

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Gain Therapeutics Inc. (GANX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 , and -100.0% cumulative change since FY2023) , GAAP net income of -$20.2M, operating cash flow of -$18.5M, and free cash flow of -$18.5M (+2.2% YoY). On the balance sheet, GANX closed FY2025 with $22.8M in total assets against $300.1K in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$20.2M	-$18.5M	-$18.5M	$22.8M	$300.1K
FY2024 (FY)	2024-12-31	$0	-$20.4M	-$18.9M	-$18.9M	$12.1M	$328.3K
FY2023 (FY)	2023-12-31	$55.2K	-$22.3M	-$18.9M	-$18.9M	—	—

3. GANX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GANX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does GANX compare to IBIO and CNTB in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for GANX?

Where is GANX trading relative to its 50-day, 200-day, and 52-week technical levels?

GANX last traded at $1.13 (-5.04% on volume of 364,662 shares), positioning the stock -29.81% below its 50-day simple moving average ($1.61) and -39.25% below its 200-day simple moving average ($1.86). Across its 52-week range of $1.11 to $4.34, GANX sits at the 0.6% percentile with a 14-day RSI of 34.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.27).

GANX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is GANX's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for GANX.

Direct Sub-Reports: GANX RQD Cockpit GANX 12M Forecast GANX Earnings & Move GANX Dividends & DRIP GANX Insiders & 13F GANX Whale Options GANX Profit Sankey GANX News & Why

ROARABLE RATING BRIEF • RQD 41/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

GANX — Gain Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: Haiku 5.5 Dossier Pipeline

As of: 2026-11-02T14:20Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD 5-pillar rating engine, Gain Therapeutics Inc. (GANX) carries a composite score of 41/100 (D- — Roarable Sell — Vulnerable Balance Sheet & Flow) at a current price of $1.13 (-5.04%). Fundamental cash generation scores 7/20 (ROIC -35.0%, FCF yield —), institutional 13F whale accumulation scores 3/20, insider conviction scores 7/20, macro regime alignment scores 11/20 (Beta 1.00), and forensic balance-sheet protection scores 13/20 (Altman Z-Score N/A, Piotroski F-Score 4/9).

Investor Implication: At current trailing P/E and current forward P/E within Biotechnology: Pharmaceutical Preparations, upside depends on sustained operating margin expansion (—) and free cash flow conversion relative to the 52-week range of $1.11 – $4.34.

Butterfly Effect: Supply-Chain, Sector & Catalyst Ripples

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), GANX is sensitive to 2nd-order capital expenditure cycles, input cost spreads (gross margin —), and institutional positioning across its peer cohort. Prospective investors should monitor quarterly order backlog conversion, sector capex guidance, and Form 4 insider cluster activity (0 recent filings tracked).

Open Questions to Watch: (1) Margin trajectory vs. peer median; (2) FCF conversion sustainability over the next 4 quarters; (3) Institutional 13F rebalancing around upcoming earnings.

GANX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Gain Therapeutics Inc. (GANX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to GANX Debate Forum (3) ↓

🟢 CATALYST Yahoo Finance • 25d ago

Gain Therapeutics to Attend the 2026 Maxim Growth Summit

BETHESDA, Md., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of a

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 32d ago

Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration

MDS-UPDRS motor scores demonstrated stability to baseline recorded at study entry with no disease progression among the 12 evaluable participants who completed 12 months of daily oral administration of rexaceract by Augu

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 33d ago

Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders

BETHESDA, Md., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 46d ago

Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference

BETHESDA, Md., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain” or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of a

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 69d ago

Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference

BETHESDA, Md., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain” or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of al

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 109d ago

Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update

BETHESDA, Md., July 16, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of a

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 125d ago

Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease

IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S., expected during 3Q26 FDA’s decision follows positive Phase 1 results for GT-02287 in both healthy volunteers and people

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 145d ago

Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit

BETHESDA, Md., June 10, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of a

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

GANX Bull vs. Bear Conversation Board — What's Your Call at $1.13?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON GANX 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.05 (-11.8%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is GANX (D- • RQD 41/100) a Buy at $1.19?

Welcome to the GANX (Gain Therapeutics Inc.) Roar Pit. Current RQD Composite is 41/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.96 (-19.3%)

Spot @ $1.19

Pump the brakes on GANX — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on GANX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Gain Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.45 (+21.8%)

Spot @ $1.19

GANX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on GANX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.19 (52-wk range $1.11 - $4.34), any beat on forward guidance forces shorts and underweight funds to chase.